DYN Dyne Therapeutics, Inc. Insider Trading

Director Brian S Posner bought 2,000 shares of Dyne Therapeutics (DYN) at $18.21 on 2026-05-26, raising holdings to 20,000 shares despite -$120.9M net income.

Brian S Posner, Director of unprofitable Dyne Therapeutics (net income: -$120,854,000.00), purchased 2,000 shares at $18.21, expanding his stake by 11.1% to 20,000 shares. His cross-ticker track record shows strong execution: 4 prior open-market buys averaged +112.9% 30-day return and +101.6% 90-day return with a 75.00% 90-day win rate. At DYN specifically, however, his timing pattern is mixed: 2 of his 3 prior DYN purchases delivered positive 90-day returns, but the most recent buy on 2026-03-30 returned only +1.9% over 30 days, and his March 11 purchase lost -10.2% over 90 days. The current stock price of $18.56 sits -25.8% from its 52-week high of $25.00 but has recovered +18.8% over the past 90 days, suggesting some stabilization after earlier declines. This purchase signals director confidence in the near-term trajectory, though the company's continued unprofitability and mixed recent timing outcomes at this ticker warrant attention.

Director Brian S Posner buys 2,500 DYN shares at $17.12; 2 of 3 prior DYN buys showed positive 90-day returns.

Director Brian S Posner purchased 2,500 shares at $17.12 on 2026-05-20, increasing his holdings to 18,000 shares (+16.1% net change). His prior transaction history at Dyne Therapeutics shows mixed results: 2 of his 3 prior DYN buys generated positive 90-day returns (+1.7% and +15.3%), though one underperformed (-10.2%). His cross-ticker track record demonstrates stronger timing with 75.00% win rate and avg 90d return +101.6%, but this current purchase arrives as the stock trades at -30.5% from its 52-week high and -11.7% over the past 30 days. The company remains unprofitable with net income of $-120.9M over its most recent fiscal year, which limits visibility into whether this buy reflects conviction in a recovery or operational turnaround.

Director Rhodes unloads ~$1.9M in DYN shares; stock well below 52-week high amid persistent insider-selling pattern and unprofitable fundamentals.

Jason P. Rhodes, a director of Dyne Therapeutics, disposed of over 106,000 shares across three trading days in early May for approximately $1.9 million total. The stock is currently trading well below its 52-week high, having declined significantly from recent peaks. This sale adds to Rhodes' long-standing pattern of open-market dispositions—he has now executed 83 open-market sales over the past 36 months, with all five of his prior sales at this specific ticker proving poorly-timed, as the stock rose following each exit. Notably, the company is unprofitable with significant annual losses, and Rhodes' sustained selling activity over an extended period suggests a consistent orientation toward reducing exposure rather than conviction about near-term upside. The combination of persistent board-level sales, weak fundamentals, and the director's poor historical timing on prior DYN exits warrants closer scrutiny of whether operational challenges are driving these dispositions.

Director Jason Rhodes sells ~228k shares of DYN for ~$4.2M across multiple tranches on single day

Jason Rhodes, a director at Dyne Therapeutics, executed a substantial multi-tranche sale of approximately 228,000 shares totaling $4.2 million on a single day. The company is currently unprofitable with significant ongoing losses, and the stock is trading well below its highs from earlier in the year. While a sale of this magnitude could suggest a director reducing exposure during a period of negative earnings momentum, the execution across eight separate transactions at marginally different prices is noteworthy—it reads more like portfolio rebalancing or a systematic liquidation plan than a panic exit. The timing coincides with a stock trading modestly above recent lows, which is neutral rather than obviously unfavorable. Without visibility into Rhodes' trade plan authorization or historical selling patterns, this requires closer inspection to determine whether this reflects concern about the company's trajectory or routine personal financial management by a board member.